Ypsomed expands to more countries

Burgdorf, (PresseBox) - Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.

Following the successful and controlled launch of the mylife™ YpsoPump® during 2016 in Germany, the Netherlands and the UK, the Management of the Ypsomed Group has decided in favour of geographic expansion. In addition to the existing home markets such as France, Italy, Switzerland, Austria and Scandinavia, the innovative insulin pump is also to be launched in Belgium, Spain and India during 2017. The mylife™ YpsoPump® is already available in Czechia since January 2017, where the subsidiary was established at the end of 2016, mainly for its distribution.

Ypsomed CEO Simon Michel justifies the investment into geographic expansion as follows: "The introduction phase of the mylife™ YpsoPump® has shown that it meets the needs of many people with diabetes. Simplicity in training and in use gives many people a certain degree of freedom and independence in their daily therapy and considerably simplifies the process in the pump centres and physicians practices. Furthermore, the competitive situation in the market for insulin pumps is extremely dynamic. Due to this development we foresee excellent opportunities of growing successfully in this highly competitive market and to continue establishing ourselves as a diabetes specialist. All good reasons to exploit important and missing markets inside and outside Europe with additional investments."

Ypsomed AG

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'300 employees. Additional information are available under www.ypsomed.com.

Press releases you might also be interested in

Weitere Informationen zum Thema "Medizintechnik":

Künstliche Intelligenz optimiert das Mobilfunknetz

Das Mo­bil­funk­netz, ein kom­ple­xes Kon­strukt aus Mo­bil­funk­stand­or­ten und Net­z­e­le­men­ten, sorgt da­für, dass Men­schen je­der­zeit und übe­rall mit­ein­an­der te­le­fo­nie­ren und ih­re di­gi­ta­len An­wen­dun­gen nut­zen kön­nen. Die In­stand­hal­tung, Über­prü­fung und Opti­mie­rung ei­ner solch viel­schich­ti­gen Struk­tur er­for­dert je­de Men­ge men­sch­li­ches und tech­ni­sches Know-how. Um kom­ple­xe Zu­sam­men­hän­ge im Mo­bil­funk­netz noch bes­ser zu ver­ste­hen, setzt Te­le­fó­ni­ca Deut­sch­land seit ei­ni­ger Zeit Al­go­rith­men und Künst­li­che In­tel­li­genz (KI) ein.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.